【摘要】 目的:研究联合依达拉奉治疗帕金森病(PD)的临床疗效。方法:将80例PD患者按Hoehn&Yahr(H&Y)分级划分为2组:早期PD组49例(1～2.5级),晚期PD组31例(3～4级),在左旋多巴等药物治疗的基础上应用依达拉奉注射液30mg加入0.9%氯化钠注射液100mL中静脉滴注,bid,连续2周。分别在治疗前和治疗后2,4,12周进行PD统一评分量表(UPDRSⅠ~Ⅲ)评分和H&Y分级评定,并观察治疗期间的不良反应。结果:(1)早期PD组在治疗后2,4,12周精神行为和情绪评分、日常活动评分和运动功能评分较治疗前有显著降低(P<0.01),H&Y分级显著下降(P<0.01),晚期PD组UP-DRSⅠ~Ⅲ评分和H&Y均无显著降低(P>0.05);(2)治疗前后比较H&Y分级中1级患者显著增多(P<0.01);(3)早期PD组治疗后12周多巴制剂用量与治疗前比较显著减少(P<0.01),晚期PD组多巴制剂无调整;(4)依达拉奉治疗期间出现轻度恶心、食欲下降2例(2.5%),谷丙转氨酶轻度升高1例(1.25%),无其他不良反应;2组患者在治疗前和治疗后2,4,12周测肝功能、肾功能、白细胞差异均无显著性(P>0.05)。结论:联合依达拉奉治疗能够短期内改善早期PD患者的症状,但对晚期PD的临床症状无明显改善。更多还原

【Abstract】 OBJECTIVE To study the clinical treatment effect of edaravone on Parkinson’s disease.METHODS 80 patients of Parkinson’s disease were divided into two groups by Hoehn&Yahr(H&Y):49 patients of early stage(1~2.5) and 31 of advanced stage(3~4).Every patient of two groups was treated by intravenous drip of edaravone injection(30mg) and saline solution(100 mL) twice per day in 2 weeks.Then the Unified Parkinson Disease Rating Scale(UPDRS Ⅰ~Ⅲ),H&Y grade assessment and adverse reactions observation of every patient were recorded before treatment and 2w,4w,12w after treatment respectively.RESULTS (1) Compared with before treatment,the mental and emotional score,daily activity and motor function score and H & Y grade of the early PD group decreased significantly 2w,4w,12w after treatment(P<0.01),but UPDRS Ⅰ~ Ⅲ score,and H & Y grade of the advanced PD group had no significant change(P>0.05).(2) Patients of H & Y grade 1 increased significantly(P<0.01) after treatment.(3) Compared with before treatment,the dopa dosage of early PD group reduced significantly 12w after treatment(P<0.01),but the dosage of advanced PD group had no adjustment.(4) During the treatment of edaravone,two felt mild nausea and lost appetite(take up 2.5%),the GPT of one patient increased slightly(take up 1.25%),and no other adverse reactions appeared.Furthermore the liver function,kidney function and leukocytes of patients in 2 groups had no significant difference(P>0.05) 2w,4w,12w after treatment.CONCLUSION The edaravone treatment can improve the short-term symptoms of early PD patients,but has no significant improvement of advanced PD patients.更多还原